Promius Pharma, LLC, a wholly owned subsidiary of Dr. Reddy's Laboratories announced the launch of its first product, EpiCeram(R) Skin Barrier Emulsion.
EpiCeram Emulsion is a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million Americans at an estimated cost of $1 billion annually. Promius Pharma launches EpiCeram Emulsion this week at the 27th Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada, attended by over 400 dermatologists and healthcare providers.
EpiCeram Emulsion is based on scientific advances in the understanding of the skin barrier and its role in the pathogenesis of atopic dermatitis. EpiCeram Emulsion provides an optimal 3:1:1 ratio of ceramides, free fatty acids and cholesterol to help repair the damaged skin barrier in order to relieve the signs and symptoms of atopic dermatitis. "We are very excited about the launch of EpiCeram Skin Barrier Emulsion," said Jeffrey Wasserstein, Executive Vice President of Promius Pharma. "This product was developed to specifically address the defective skin barrier of atopic patients to safely and effectively control the signs and symptoms of atopic dermatitis. We are proud that EpiCeram Emulsion is our first commercialized product because it aligns with our core strategy of striving to meet unmet medical needs. EpiCeram has the potential to change how doctors treat mild to moderate atopic dermatitis."